Venture: Biotechnology
Issue 132; Biotech is still showing signs of strength, and we add another gem to the portfolio.
Issue 132; Biotech is still showing signs of strength, and we add another gem to the portfolio.
Issue 131; Biotech is on the move once again, and one small niche in particular. After the dotcom bust in
Issue 130; The price of gold has retreated this year 25% from its peak in January at $5,417. Having
Today, we take profits on one of our best-performing holdings, Seraphim Space Investment Trust (SSIT).
The curious thing about the latest rally is how the market has been so strong despite having such weak breadth. This week, we are reducing some risk.
Today, I offer a short update on a portfolio holding.